Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
261 stopped studies mapped to Head and Neck Squamous Cell Carcinoma and descendants · 95% state a reason
Over the 261 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04459715 | A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and… | Phase 3 | terminated | Jul 7, 2020 | EMD Serono Research & Development Institute, Inc. | Study has crossed the pre-defined futility boundary at the Interim Analysis. | Efficacy / futility |
| NCT04458909 | Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual… | Phase 3 | terminated | Jul 7, 2020 | National Cancer Institute (NCI) | External information | Other (stated, no rule matched) |
| NCT04000529 | Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected… | Phase 1 | terminated | Jun 27, 2019 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
| NCT05061420 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of… | Phase 2 | terminated | Sep 29, 2021 | Sanofi | Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Safety / toxicity |
| NCT06285097 | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced… | Phase 1 | terminated | Feb 29, 2024 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT06338657 | FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer | Phase 1 | terminated | Mar 29, 2024 | University of Southern California | Slow accrual | Enrollment / accrual |
| NCT04989387 | Study of INCA 0186 in Subjects With Advanced Solid Tumors | Phase 1 | terminated | Aug 4, 2021 | Incyte Corporation | This was a strategic business decision. There were no safety concerns contributing to this decision. | Safety / toxicity |
| NCT05605522 | A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | Phase 1 | terminated | Nov 4, 2022 | 3B Pharmaceuticals GmbH | Sponsor reprioritization of active trials. | Other (stated, no rule matched) |
| NCT03729596 | MGC018 With or Without MGA012 in Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Nov 2, 2018 | MacroGenics | Business decision | Sponsor / business decision |
| NCT06362421 | Saliva Testing for High-Risk Human Papillomavirus Infection Oral Cavity and Pharynx Cancer | — | withdrawn | Apr 12, 2024 | Wake Forest University Health Sciences | PI not moving forward with study at our institution | Other (stated, no rule matched) |
| NCT02892201 | Pembrolizumab in HNSCC With Residual Disease After Radiation | Phase 2 | terminated | Sep 8, 2016 | Yale University | Low enrollment | Enrollment / accrual |
| NCT06086925 | A Window of Opportunity Study of Black Raspberry for Patients With HNSCC | Early Phase 1 | withdrawn | Oct 17, 2023 | Mitchell Machtay | The study was not initiated due to funding constraints and will not proceed in its current design. | Funding |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | Phase 2 | terminated | Oct 3, 2022 | Telix Pharmaceuticals (Innovations) Pty Ltd | Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic… | Other (stated, no rule matched) |
| NCT05879484 | Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative… | Phase 1 / Phase 2 | withdrawn | May 30, 2023 | National Cancer Institute (NCI) | Study was never opened for enrollment as the CRADA was never executed | Enrollment / accrual |
| NCT03440437 | A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies | Phase 1 / Phase 2 | terminated | Feb 22, 2018 | invoX Pharma Limited | Business Decision | Sponsor / business decision |
| NCT05432193 | FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry… | Phase 1 | terminated | Jun 27, 2022 | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | Business decision | Sponsor / business decision |
| NCT03094169 | AVID100 in Advanced Epithelial Carcinomas | Phase 1 / Phase 2 | terminated | Mar 29, 2017 | Formation Biologics | lack of efficacy | Efficacy / futility |
| NCT01720563 | A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell… | Phase 2 | terminated | Nov 2, 2012 | PhytoHealth Corporation | Change study drug dosage form | Other (stated, no rule matched) |
| NCT04152018 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Phase 1 | terminated | Nov 5, 2019 | Pfizer | Study termination was based on strategic considerations and not due to specific safety reasons or a… | Safety / toxicity |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Jun 22, 2020 | Numab Therapeutics AG | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT04633278 | CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head… | Phase 2 | terminated | Nov 18, 2020 | Regeneron Pharmaceuticals | Business Decision | Sponsor / business decision |
| NCT05930938 | Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients…(XXL_2022-01) | Phase 3 | terminated | Jul 5, 2023 | Groupe Oncologie Radiotherapie Tete et Cou | toxicity | Safety / toxicity |
| NCT03053960 | Helical CT, PET/CT, MRI, and CBCT Alone or in Combination in Predicting Jaw Invasion in… | — | terminated | Feb 15, 2017 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Terminated by IRB | Other (stated, no rule matched) |
| NCT04595981 | Chemo-embolization for Head and Neck Cancer | Phase 2 | withdrawn | Oct 22, 2020 | University of Alabama at Birmingham | No staff or funding to do the study. | Funding |
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors(RAPTOR) | Phase 1 | terminated | Mar 9, 2020 | Turnstone Biologics, Corp. | Sponsor decision | Sponsor / business decision |
| NCT05322135 | A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell Carcinoma | Early Phase 1 | terminated | Apr 11, 2022 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT05608369 | Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC(HPV) | Phase 2 | withdrawn | Nov 8, 2022 | Case Comprehensive Cancer Center | PI left | Investigator |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab… | Phase 1 / Phase 2 | terminated | Feb 4, 2019 | Kymab Limited | Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Safety / toxicity |
| NCT05452408 | Antitumor-B KAC PK Study | Phase 1 | withdrawn | Jul 11, 2022 | Medical College of Wisconsin | Study abandoned. | Other (stated, no rule matched) |
| NCT02827838 | Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer | Early Phase 1 | terminated | Jul 11, 2016 | Wake Forest University Health Sciences | Study closed prior to meeting enrollment goal and funding issues | Enrollment / accrual |
| NCT05743270 | Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With… | Phase 2 | withdrawn | Feb 24, 2023 | Replimune, Inc. | Sponsor decision | Sponsor / business decision |
| NCT04032704 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | Phase 2 | terminated | Jul 25, 2019 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT05576077 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors(STARLING) | Phase 1 | terminated | Oct 12, 2022 | Turnstone Biologics, Corp. | Sponsor decision | Sponsor / business decision |
| NCT03169764 | QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination… | Phase 1 / Phase 2 | withdrawn | May 30, 2017 | ImmunityBio, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT04465487 | Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies | Phase 1 | terminated | Jul 10, 2020 | Regeneron Pharmaceuticals | Sponsor Decision | Sponsor / business decision |
| NCT04502888 | Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell… | Phase 1 | terminated | Aug 6, 2020 | Shattuck Labs, Inc. | Sponsor decision | Sponsor / business decision |
| NCT06054477 | Study of ALE.C04 in Patients With Head and Neck Cancer | Phase 1 / Phase 2 | terminated | Sep 26, 2023 | Alentis Therapeutics AG | Reprioritization of Trial | Other (stated, no rule matched) |
| NCT04588038 | NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing… | Phase 1 | terminated | Oct 19, 2020 | Hyunseok Kang, MD | Slow Accrual | Enrollment / accrual |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | Phase 1 | terminated | Feb 5, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT05457478 | The Use of "Smart" Body-Weight Scales for Weight and Nutritional Monitoring in Patients… | N/A | terminated | Jul 14, 2022 | OHSU Knight Cancer Institute | PI departure | Other (stated, no rule matched) |
| NCT03769467 | Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr… | Phase 1 / Phase 2 | terminated | Dec 7, 2018 | Atara Biotherapeutics | Phase 1B part was completed with review of DLTs and cumulative safety data by Safety Data Review… | Safety / toxicity |
| NCT04220775 | Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or… | Phase 1 / Phase 2 | terminated | Jan 7, 2020 | M.D. Anderson Cancer Center | The sponsor decided to no longer develop the drug and stop support of studies using the drug. | Sponsor / business decision |
| NCT04795713 | Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 | Phase 1 | terminated | Mar 12, 2021 | Molecular Templates, Inc. | Terminated by Sponsor | Other (stated, no rule matched) |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With… | Phase 1 | terminated | Sep 13, 2023 | Molecular Templates, Inc. | Sponsor Termination | Other (stated, no rule matched) |
| NCT03153982 | Ruxolitinib in Operable Head and Neck Cancer | Phase 2 | terminated | May 15, 2017 | University of California, San Francisco | Low accrual | Enrollment / accrual |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors…(PDL1x41BB) | Phase 1 | terminated | Jan 18, 2019 | Inhibrx Biosciences, Inc | Program terminated due to lack of meaningful efficacy signal. | Efficacy / futility |
| NCT03452137 | A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local…(IMvoke010) | Phase 3 | terminated | Mar 2, 2018 | Hoffmann-La Roche | Decision to terminate the study as its primary endpoint of investigator-assessed event free… | Safety / toxicity |
| NCT04628780 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 16, 2020 | Pfizer | Pfizer has made an internal business decision to not continue further development of PF-07209960.… | Safety / toxicity |
| NCT06084845 | Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy… | Phase 2 | withdrawn | Oct 16, 2023 | ECOG-ACRIN Cancer Research Group | A phase III trial of the investigational agent failed to pass futility boundaries at interim… | Efficacy / futility |
| NCT06357858 | ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck | Phase 1 | withdrawn | Apr 10, 2024 | Case Comprehensive Cancer Center | Funding unavailable | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Oct 8, 2025source: clinicaltrials